International Myeloma Foundation
Advocacy Update | July 2021
capitol hill with action center button
Pills on bills
Cancer Drug Parity Act Reintroduced
On July 9, 2021, H.R. 4385, the Cancer Drug Parity Act was reintroduced in the House of Representatives by Representatives Brian Higgins (D-NY), Brett Guthrie (R-KY), Joe Morelle (D-NY), Glenn Grothman (R-WI), Doris Matsui (D-CA) and Gus Bilirakis (R-FL). The bill would protect the approximately 140 million patients covered by federally regulated group health plans by ending the preference for cancer care that is not administered orally.

Orally administered anticancer medications are used to treat many cancers, including multiple myeloma. This bill would help patients with group health insurance plans access these drugs by ensuring fairness in cost-sharing for all anticancer regimens, ultimately reducing their out-of-pocket expenses.

To let the House of Representatives know you support this bill, please click HERE.
us-capitol.jpg
IMF Sends CURES 2.0 Letter Advocating for Parity
Representative Upton and Representative DeGette recently released a discussion draft to their legislative proposal entitled CURES 2.0. According to Representative DeGette, the bill “seeks to build upon the tremendous success DeGette and Upton had in 2015 with passage of their 21st Century Cures Act, a landmark piece of legislation that has revolutionized how the U.S. researches and develops new cures and treatments for some of the world’s most difficult diseases.” The bill also focuses on accessibility of cures to patients.

Robin Roland Levy, IMF’s Senior Director of Public Policy and Advocacy wrote to DeGette and Upton expressing the IMF’s support for addressing the access issues patients taking oral chemotherapy drugs face, and expressing our support for the Cancer Drug Parity Act. To read the IMF letter please click HERE and to read more about the legislation click HERE.
medicare blocks
Cassidy Menendez OOP Cap
On July 14, 2021, Senator Bill Cassidy (R-LA) and Sen. Bob Menendez (D-NJ) introduced, S. 2327, the Seniors Prescription Drug Relief Act, legislation that would create an out-of-pocket cap for Medicare patients. This would essentially create a yearly limit on how much a patient would pay for their prescription drugs.

As a result of the current structure of Medicare Part D, many myeloma patients face issues accessing their medications because of their struggle to afford their out-of-pocket expenses. The creation of an out-of-pocket cap would provide certainty to patients because they could predict exactly how much they owe for their medications.

To view more about the legislation click HERE and to let your Members of Congress know you support an out-of-pocket cap in Medicare, click HERE.
 

Want to get involved?

Interested in learning more or taking actions about our federal and/or state priorities? Email the IMF Advocacy Team, advocacy@myeloma.org, to find out ways you can help and make your voice heard. Find us on the Twitter and Facebook! We will be sharing the latest news on legislation and policies we are tracking. And follow @Chemoparity for updates on our fight to get oral parity passed at the state and federal levels.
Get_Involved.png
 

We Thank Our Sponsor:

Bristol-Myers Squibb
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter: @IMFMyeloma  |  Instagram Instagram: @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page